MAM
ADMA icon

Meeder Asset Management’s ADMA Biologics ADMA Stock Holding History

Meeder Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$87.9K Sell
9,759
-702
-7% -$11.1K 0.01% 379
2025
Q4 		$191K Buy
+10,461
New +$176K 0.01% 273
2024
Q4 		– Sell
-454
Closed -$9.07K – 901
2024
Q3 		$9.07K Buy
+454
New +$7.06K ﹤0.01% 639
2021
Q4 		– Sell
-1,008
Closed -$1K – 1109
2021
Q3 		$1K Hold
1,008
– – ﹤0.01% 2268
2021
Q2 		$2K Hold
1,008
– – ﹤0.01% 2175
2021
Q1 		$1K Buy
+1,008
New +$2.31K ﹤0.01% 2164
2020
Q2 		– Sell
-2,202
Closed -$6K – 2014
2020
Q1 		$6K Buy
2,202
+710
+48% +$2.45K ﹤0.01% 1695
2019
Q4 		$6K Sell
1,492
-30
-2% -$131 ﹤0.01% 1700
2019
Q3 		$7K Buy
1,522
+233
+18% +$974 ﹤0.01% 1628
2019
Q2 		$5K Buy
1,289
+303
+31% +$1.34K ﹤0.01% 1648
2019
Q1 		$4K Buy
986
+157
+19% +$555 ﹤0.01% 1424
2018
Q4 		$2K Sell
829
-251
-23% -$1.24K ﹤0.01% 1557
2018
Q3 		$7K Buy
1,080
+684
+173% +$3.94K ﹤0.01% 1233
2018
Q2 		$1.79K Buy
+396
New +$1.97K ﹤0.01% 1430

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Meeder Asset Management's ADMA Position: Q1 2026 in Review

Meeder Asset Management reduced its ADMA Biologics (ADMA) stake by 6.7% in Q1 2026, selling an estimated $11.1K and leaving 9,759 shares worth $87.9K. The position accounts for 0.01% of the portfolio, ranked #379.

Meeder Asset Management first reported a position in ADMA in Q2 2018 and has held it in 14 quarters since. The position peaked at $191K in Q4 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Meeder Asset Management held 9,759 shares of ADMA Biologics worth $87.9K as of Q1 2026.
  • Meeder Asset Management sold 702 ADMA Biologics shares in Q1 2026, an estimated $11.1K.
  • ADMA Biologics made up 0.01% of Meeder Asset Management's portfolio in Q1 2026, its #379 holding.
  • Meeder Asset Management first reported a position in ADMA Biologics in Q2 2018 and has held it in 14 quarters since.
  • Meeder Asset Management's ADMA Biologics position peaked at $191K in Q4 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.